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We read with interest the paper by Hasin et al. (1), which reported
improvement in renal function after left ventricular assist device
(LVAD) implantation. Although the investigators demonstrated
significant improvement in most patients, renal failure after
LVAD implantation is associated with significant complications
(2). In this study, 8 patients (10%) required long-term dialysis after
LVAD—4 of whom died after implantation; the remaining 4 had
prolonged hospitalizations (51  17 days). Although renal failure
is infrequent, it is associated with significant morbidity and
mortality. For this reason, patients with advanced renal failure are
typically not considered for LVAD implantation. Renal failure,
even if infrequent, can significantly increase resource utilization at
a time when health care expenditures are being scrutinized. Several
studies have questioned the cost-effectiveness of LVAD therapy
(3,4). Nevertheless, with appropriate patient selection, longer term
benefits, such as improved renal function, can outweigh short-term
morbidity.
Another concern is the reluctance of outpatient dialysis centers
to accept LVAD patients. In our experience, this leads to pro-
longed length of stay and is detrimental to patient quality of life.
There are limited data regarding the safety of hemodialysis in
LVAD patients (5). Similar to the investigators, we supported
several patients with intermittent hemodialysis until renal recovery
without significant complications. Concerns among nephrologists
stem from unfamiliarity with LVADs and perceived difficulties in
measuring blood pressure on continuous flow support. Further
data are needed to demonstrate the safety of hemodialysis and to
alleviate the concerns of nephrologists.
Hasin et al. (1) observed a slight decrease in renal function at 6
months post-implantation compared with 1 month. For some
patients on long-term LVAD support, eventual renal failure will
result and, depending upon patient age and other comorbidities,
transplantation may not be an option. Although some patients may
live near their implantation centers and receive dialysis there,
others will require the care of community dialysis centers. Outpa-
tient dialysis centers must care for these patients, so they continue
to experience the quality-of-life benefit seen with LVAD support.
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Reply
We thank Drs. Rajagopalan and Hoopes for their letter discussing
our recent publication (1), and agree with their main observations.
They chose to highlight the adverse outcomes of patients suc-
cumbing to renal failure after left ventricular assist device (LVAD)
implantation and the current limitations of administering long-
term renal support for patients assisted with such a device. In our
experience, a minority of patients experience an unfavorable
post-operative course, including end organ dysfunction. This can
be reversible at times; however, renal damage may persist despite
general clinical improvement. Unfortunately, it remains difficult to
predict which patients will have this complicated post-operative
course. Currently used predictors include careful assessment of
right ventricular function as well as various risk scores, some of
which are outdated or not validated for the current population (2).
In our current publication, we advocate that temporary end organ
improvement under monitored treatment may be a novel way for
predicting post-operative outcomes.
Accurate prediction of outcomes in all patients is not feasible;
therefore, we agree with the authors on the need to be prepared for
the option of renal replacement, if needed. We have also encoun-
tered difficulties with reluctance of some dialysis centers to treat
patients on LVAD support. Continued education and understand-
ing is needed to improve the treatment of this rapidly growing
patient population.
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